Terms: = Cervical cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
207 results:
1. Integrated In-Silico and In Vitro analysis to Decipher the contribution of bisphenol-A in cervical cancer.
Khan NG; Adiga D; Rai PS; Kabekkodu SP
Toxicology; 2024 May; 504():153791. PubMed ID: 38555994
[TBL] [Abstract] [Full Text] [Related]
2. Cyclic increase in the ADAMTS1-L1CAM-egfr axis promotes the EMT and cervical lymph node metastasis of oral squamous cell carcinoma.
Chien MH; Yang YC; Ho KH; Ding YF; Chen LH; Chiu WK; Chen JQ; Tung MC; Hsiao M; Lee WJ
Cell Death Dis; 2024 Jan; 15(1):82. PubMed ID: 38263290
[TBL] [Abstract] [Full Text] [Related]
3. Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer.
Zhou J; Li H; Wu B; Zhu L; Huang Q; Guo Z; He Q; Wang L; Peng X; Guo T
Sci Rep; 2024 Jan; 14(1):1860. PubMed ID: 38253629
[TBL] [Abstract] [Full Text] [Related]
4. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
5. Survival rate of cervical cancer in Asian countries: a systematic review and meta-analysis.
Vali M; Maleki Z; Nikbakht HA; Hassanipour S; Kouhi A; Nazemi S; Hajizade-Valokolaee M; Nayeb M; Ghaem H
BMC Womens Health; 2023 Dec; 23(1):671. PubMed ID: 38098009
[TBL] [Abstract] [Full Text] [Related]
6. Exploration of the Mechanism of Kaempferol in the treatment of cervical cancer-based on Metabolomics and Network Pharmacology.
Cao DM; Liu T
Curr Pharm Des; 2023; 29(36):2877-2890. PubMed ID: 38062663
[TBL] [Abstract] [Full Text] [Related]
7. EGCG attenuate EGF triggered matrix abundance and migration in HPV positive and HPV negative cervical cancer cells.
Sabanayagam R; Krishnamoorthy S; Gnanagurusamy J; Muruganatham B; Muthusami S
Med Oncol; 2023 Aug; 40(9):261. PubMed ID: 37544940
[TBL] [Abstract] [Full Text] [Related]
8. Study on the mechanism of Shujin Tongluo granules in treating cervical spondylosis based on network pharmacology and molecular docking.
Wang Y; Tao X; Gao Y; Jin Z; Guo S; Li Z; Wang M; Zhao R; Zhou W; Wu J
Medicine (Baltimore); 2023 Jul; 102(29):e34030. PubMed ID: 37478234
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of egfr inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report.
Krishna A; Sathya M; Mukesh S; Athiyamaan MS; Banerjee S; Sunny J; Srinivas C; Lobo D; Makkapatti BS; Jawahar V
Med Oncol; 2023 Jun; 40(7):203. PubMed ID: 37310466
[TBL] [Abstract] [Full Text] [Related]
10. Suppression of human papillomavirus type 16 E5 oncoprotein: A promising step in fostering the treatment of cervical cancer.
Hemmat N; Doustvandi MA; Asadzadeh Z; Mokhtarzadeh A; Baradaran B; Baghi HB
Oncol Res; 2021; 29(2):141-148. PubMed ID: 37305401
[TBL] [Abstract] [Full Text] [Related]
11. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract] [Full Text] [Related]
12. LY6K depletion modulates TGF-β and EGF signaling.
Park S; Park D; Han S; Chung GE; Soh S; Ka HI; Joo HJ; Yang Y
Cancer Med; 2023 Jun; 12(11):12593-12607. PubMed ID: 37076981
[TBL] [Abstract] [Full Text] [Related]
13. Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy.
Ao M; Li P; Sun D; Li X; Xu S; Hao Y
J Obstet Gynaecol; 2023 Dec; 43(1):2179915. PubMed ID: 37001548
[TBL] [Abstract] [Full Text] [Related]
14. Integrating network pharmacology approaches for the investigation of multi-target pharmacological mechanism of 6-shogaol against cervical cancer.
Elasbali AM; Al-Soud WA; Mousa Elayyan AE; Al-Oanzi ZH; Alhassan HH; Mohamed BM; Alanazi HH; Ashraf MS; Moiz S; Patel M; Patel M; Adnan M
J Biomol Struct Dyn; 2023; 41(23):14135-14151. PubMed ID: 36943780
[TBL] [Abstract] [Full Text] [Related]
15. ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing.
Machida H; Matsuo K; Tanaka M; Kitatani K; Takase A; Yokoyama K; Kajiwara H; Yasaka M; Ikeda M; Yoshida H; Hirasawa T; Mikami M
Gynecol Oncol; 2023 Apr; 171():59-66. PubMed ID: 36804622
[TBL] [Abstract] [Full Text] [Related]
16. Acquisition of Genetic Aberrations During the Progression of High-Grade Intraepithelial Lesions/Micro-Invasive Squamous cancers to Widely Invasive cervical Squamous Cell cancer.
Kashofer K; Reich O; Regauer S
Arch Pathol Lab Med; 2023 Dec; 147(12):1438-1445. PubMed ID: 36800542
[TBL] [Abstract] [Full Text] [Related]
17. Resveratrol against cervical cancer: Evidence from In Vitro and In Vivo Studies.
Nadile M; Retsidou MI; Gioti K; Beloukas A; Tsiani E
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558430
[TBL] [Abstract] [Full Text] [Related]
18. An integrative approach toward identification and analysis of therapeutic targets involved in HPV pathogenesis with a focus on carcinomas.
Gupta AK; Kumar M
Cancer Biomark; 2023; 36(1):31-52. PubMed ID: 36245368
[TBL] [Abstract] [Full Text] [Related]
19. Robot-assisted Laparoscopic Bilateral Ileal Ureter in Duplex Ureter With Strictures After treatment Failure of Allium Stents.
Li X; Wang X; Chen S; Li Z; Yang K; Li X
Urology; 2022 Nov; 169():267-268. PubMed ID: 36002090
[TBL] [Abstract] [Full Text] [Related]
20. A Novel Prognostic Risk Model for cervical cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
Xu HH; Wang HL; Xing TJ; Wang XQ
Front Immunol; 2022; 13():851622. PubMed ID: 35924232
[TBL] [Abstract] [Full Text] [Related]
[Next]
